Medical News Today -
17 Feb 2014 12:00
Actelion Ltd has announced that SwissMedic has approved Opsumit® (macitentan) for PAH patients within Switzerland.Opsumit is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in patients of WHO Functional Class II to III to reduce morbidity and the risk of mortality.Opsumit is effective when used as monotherapy or in combination with phosphodiesterase-5 inhibitors or inhaled / oral prostanoids.
Share this Article